Bristol Myers price target raised to $40 from $37 at Morgan Stanley

Morgan Stanley expert Terence Flynn raised the firm’s price target connected Bristol Myers (BMY) to $40 from $37 and keeps an Underweight standing connected the shares. 2026 gross and EPS guidance came successful supra consensus, but was driven by a higher than expected Eliquis guide, the expert tells investors successful a probe note.

Claim 50% Off TipRanks Premium

• Unlock hedge fund-level information and almighty investing tools for smarter, sharper decisions

• Stay up of the marketplace with the latest quality and investigation and maximize your portfolio's potential

Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>

See today’s best-performing stocks connected TipRanks >>

Read More connected BMY:

Disclaimer & DisclosureReport an Issue

• Trump Trade: Argentina says U.S. to chopped hundreds of tariffs

• Bristol Myers terms people raised to $68 from $64 astatine BofA

• Bristol Myers terms people raised to $72 from $62 astatine Guggenheim

• Bristol Myers terms people raised to $64 from $60 astatine Citi

• Bristol Myers terms people raised to $60 from $55 astatine Wells Fargo